Palisade Bio Announces Inducement Awards Under Inducement Plan for Key New Hires
CARLSBAD, Calif., May 10, 2022 (GLOBE NEWSWIRE) -- Palisade Bio (Nasdaq: PALI), a clinical-stage biopharmaceutical company advancing therapies for acute and chronic gastrointestinal complications, today announced that it had made equity grants to four new employees under its 2021 Inducement Plan.
On?May 4, 2022, the Company’s Compensation Committee granted options to four new non-executive employees covering an aggregate of 140,000 shares of the Company’s common stock as an inducement for such employees to join the Company.
The options have an exercise price equal to the closing price of the Company’s common stock on the date of grant. The options granted to each employee vest in equal proportions each quarter for three years. In all cases, the options are contingent on each employee’s continued service with the Company at the applicable vesting date.
About Palisade Bio
Palisade Bio Contact
Investor Relations Contact
Source: Palisade Bio
Keynote Presentation by Intelisys - Open to all Badge Holders
How Blockchain Enables Decentralized Identity
Solving Future of Work Challenges for Frontline Workers